|
JP2016500255A
(ja)
|
2012-12-11 |
2016-01-12 |
アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ |
ハイスループットなレセプター：リガンド同定の方法
|
|
MX378790B
(es)
*
|
2014-07-21 |
2025-03-10 |
Delinia Inc |
Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
|
|
SG11201700629TA
(en)
|
2014-08-11 |
2017-02-27 |
Delinia Inc |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
IL283764B2
(en)
|
2015-04-10 |
2024-01-01 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
CN109071623B
(zh)
*
|
2016-05-04 |
2022-05-27 |
美国安进公司 |
用于扩增t调节性细胞的白细胞介素-2突变蛋白
|
|
US11339201B2
(en)
|
2016-05-18 |
2022-05-24 |
Albert Einstein College Of Medicine |
Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
|
|
JP7071288B2
(ja)
|
2016-05-18 |
2022-05-18 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
WO2018089420A1
(en)
*
|
2016-11-08 |
2018-05-17 |
Delinia, Inc. |
Il-2 variants for the treatment of autoimmune diseases
|
|
CN110177564A
(zh)
*
|
2016-12-13 |
2019-08-27 |
德里尼亚公司 |
多价的调节t细胞调节剂
|
|
MX2019007611A
(es)
|
2016-12-22 |
2020-07-29 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
|
|
EP3565829A4
(en)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
EP3596108A4
(en)
|
2017-03-15 |
2020-12-23 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
|
CN118453840A
(zh)
|
2017-03-15 |
2024-08-09 |
库尔生物制药有限公司 |
用于调节免疫应答的方法
|
|
JP7001285B2
(ja)
*
|
2017-03-29 |
2022-01-19 |
国立大学法人 宮崎大学 |
長時間作用型アドレノメデュリン誘導体
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
US20200299349A1
(en)
|
2017-11-21 |
2020-09-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Partial agonists of interleukin-2
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
BR112020011343A2
(pt)
*
|
2017-12-06 |
2020-11-17 |
Pandion Therapeutics, Inc. |
muteínas de il-2 e seus usos
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
EP3728302A1
(en)
|
2017-12-19 |
2020-10-28 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
|
KR102740971B1
(ko)
|
2017-12-27 |
2024-12-11 |
쿄와 기린 가부시키가이샤 |
Il-2 개변체
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2019144309A1
(en)
*
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine Fusion Proteins
|
|
CN112105632A
(zh)
|
2018-01-24 |
2020-12-18 |
北京智康博药肿瘤医学研究有限公司 |
细胞因子融合蛋白
|
|
WO2019158764A1
(en)
|
2018-02-16 |
2019-08-22 |
Iltoo Pharma |
Use of interleukin 2 for treating sjögren's syndrome
|
|
BR112020018709A2
(pt)
|
2018-03-28 |
2021-01-05 |
Bristol-Myers Squibb Company |
Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
|
|
EP3552738B1
(en)
*
|
2018-04-12 |
2024-07-31 |
Sandvik Machining Solutions AB |
A method of producing an additive manufactured object
|
|
CN112638406B
(zh)
|
2018-06-22 |
2025-04-22 |
科优基因公司 |
白介素-2变体及其使用方法
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
WO2020023702A1
(en)
|
2018-07-25 |
2020-01-30 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
BR122021012517A2
(pt)
|
2018-08-06 |
2021-08-10 |
Medikine, Inc. |
Ligante il-2rgamac, composto compreendendo referido ligante, composição farmacêutica e uso do referido ligante
|
|
US12403181B2
(en)
|
2018-08-13 |
2025-09-02 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
|
EP3875475A4
(en)
*
|
2018-12-21 |
2022-12-07 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
VARIANT OF HUMAN INTERLEUKIN-2 OR ITS DERIVATIVE
|
|
MX2021008958A
(es)
|
2019-02-01 |
2021-11-04 |
Regeneron Pharma |
Proteínas de unión a antígeno del receptor gamma anti-il2.
|
|
JP2022520632A
(ja)
|
2019-02-15 |
2022-03-31 |
インテグラル・モレキュラー・インコーポレイテッド |
共通軽鎖を含む抗体及びその使用
|
|
KR20210128443A
(ko)
|
2019-02-15 |
2021-10-26 |
인테그럴 몰큘러 인코포레이티드 |
클라우딘 6 항체 및 이의 용도
|
|
TW202110885A
(zh)
|
2019-05-20 |
2021-03-16 |
美商潘迪恩治療公司 |
靶向ＭＡｄＣＡＭ之免疫耐受性
|
|
WO2020252264A1
(en)
|
2019-06-12 |
2020-12-17 |
AskGene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
|
PH12022550165A1
(en)
|
2019-07-26 |
2023-05-08 |
Visterra Inc |
Interleukin-2 agents and uses thereof
|
|
JP7690458B2
(ja)
*
|
2019-08-12 |
2025-06-10 |
アスクジーン・ファーマ・インコーポレイテッド |
優先的にｉｌ－２ｒアルファに結合するｉｌ－２融合タンパク質
|
|
EP4055036A4
(en)
|
2019-11-05 |
2024-02-28 |
Medikine, Inc. |
DUAL IL-2R AND IL-7R BINDING CONNECTIONS
|
|
AU2020380296A1
(en)
|
2019-11-05 |
2022-06-16 |
Medikine Inc. |
IL-2RβγC binding compounds
|
|
BR112022011414A2
(pt)
*
|
2019-12-12 |
2022-08-30 |
Iltoo Pharma |
Construção quimérica, proteína homodimérica, proteína heterodimérica, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma proteína dimérica e para produzir uma proteína heterodimérica
|
|
TW202136317A
(zh)
|
2019-12-20 |
2021-10-01 |
美商再生元醫藥公司 |
新穎之ｉｌ２促效劑及其使用方法（二）
|
|
CA3166509A1
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Biased il2 muteins methods and compositions
|
|
JP2023514128A
(ja)
|
2020-02-03 |
2023-04-05 |
メディカイン、インコーポレイテッド |
ＩＬ－７Ｒαγｃ結合化合物
|
|
AU2021217959A1
(en)
|
2020-02-03 |
2022-08-18 |
Medikine, Inc. |
IL-7Rα binding compounds
|
|
WO2021168079A1
(en)
|
2020-02-21 |
2021-08-26 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a cd39 effector
|
|
US11028132B1
(en)
|
2020-04-07 |
2021-06-08 |
Yitzhak Rosen |
Half-life optimized linker composition
|
|
TW202208395A
(zh)
|
2020-05-12 |
2022-03-01 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
JP2023526282A
(ja)
|
2020-05-13 |
2023-06-21 |
ボナム セラピューティクス，インク． |
タンパク質複合体の組成物及びその使用方法
|
|
EP4208474A2
(en)
*
|
2020-09-01 |
2023-07-12 |
Takeda Pharmaceutical Company Limited |
Interleukin-2 muteins and uses thereof
|
|
JP2023541366A
(ja)
|
2020-09-09 |
2023-10-02 |
キュー バイオファーマ， インコーポレイテッド |
１型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
EP4232071A4
(en)
|
2020-10-23 |
2024-08-28 |
Asher Biotherapeutics, Inc. |
FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
|
|
IL302114A
(en)
|
2020-10-29 |
2023-06-01 |
Bristol Myers Squibb Co |
Fusion proteins for the treatment of disease
|
|
AU2021379816A1
(en)
|
2020-11-13 |
2023-06-22 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof
|
|
MX2023006599A
(es)
|
2020-12-04 |
2023-06-19 |
Visterra Inc |
Metodos de uso de agentes de interleucina-2.
|
|
IL304365B2
(en)
*
|
2021-03-31 |
2025-04-01 |
Hanmi Pharmaceutical Co Ltd |
A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
|
|
CA3216364A1
(en)
|
2021-04-09 |
2022-10-13 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
|
|
KR20240113459A
(ko)
|
2021-10-06 |
2024-07-22 |
일투 파마 |
염증 조직에 대한 표적화 특이성을 갖는 인터루킨 2 키메라 구성체
|
|
WO2023133319A1
(en)
|
2022-01-10 |
2023-07-13 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023172628A1
(en)
|
2022-03-09 |
2023-09-14 |
Selecta Biosciences, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
|
|
US20230372535A1
(en)
|
2022-03-25 |
2023-11-23 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
US11999771B2
(en)
|
2022-04-07 |
2024-06-04 |
Medikine, Inc. |
IL-7Rαγc ligand immunoglobulin fusion proteins
|
|
WO2023196566A1
(en)
|
2022-04-08 |
2023-10-12 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
|
|
CN115322260B
(zh)
*
|
2022-06-13 |
2026-02-10 |
杭州高田生物医药有限公司 |
能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用
|
|
CA3265946A1
(en)
|
2022-09-12 |
2024-03-21 |
Sorbonne Universite |
INTERLEUKIN-2 FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS
|
|
KR20250114330A
(ko)
|
2022-11-30 |
2025-07-29 |
인테그럴 몰큘러 인코포레이티드 |
클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식
|
|
WO2024151515A2
(en)
|
2023-01-09 |
2024-07-18 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2024229370A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Compositions and methods for treating gvhd
|
|
WO2024229432A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
|
|
WO2024229380A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
|
|
WO2024229350A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2026006809A1
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Multispecific molecules binding tnfr2 and cd25 and uses thereof
|